Biohaven
BHVN
12.39
-1.26
-9.23%
Biohaven
US · BHVN
#2805 by market cap
Listed 2017
12.39
-1.26
-9.23%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Revenue annual, last 6 years
Key ratios & quality
- Enterprise valuei
- 1.80B
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 16.05M | 37.41M | 130.86M | 62.77M | 89.24M | 110.31M |
| Research & development | 98.46M | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
| Operating profit | -114.51M | -218.90M | -567.93M | -436.05M | -885.11M | -745.38M |
| Pretax profit | -118.67M | -212.43M | -569.84M | -409.55M | -845.69M | -737.38M |
| Tax | 0 | 1.37M | 438.00K | -1.38M | 735.00K | 1.44M |
| Net profit | -118.67M | -213.80M | -570.28M | -408.17M | -846.42M | -738.82M |
| Basic EPS | -3 | -6 | -13 | -6 | -9 | -7 |
| Diluted EPS | -3.31 | -5.97 | -12.75 | -5.73 | -9.28 | -6.86 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 27.33M | 28.21M | 20.79M | 26.60M | 24.09M | 24.57M |
| Research & development | 184.37M | 141.17M | 121.95M | 103.83M | 100.81M | 101.85M |
| Operating profit | -211.70M | -169.38M | -142.73M | -130.43M | -124.90M | -126.42M |
| Pretax profit | -197.89M | -173.22M | -145.20M | -130.26M | -136.92M | -129.34M |
| Tax | 261.00K | 221.00K | 351.00K | 272.00K | 391.00K | -64.00K |
| Net profit | -198.15M | -173.44M | -145.56M | -130.53M | -137.31M | -129.28M |
| Basic EPS | -2 | -2 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.94 | -1.64 | -1.21 | -0.88 | -0.91 | -0.86 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 89.76M | 94.82M | 586.97M | 442.45M | 538.47M | 368.33M |
| Cash & ST investments | 82.51M | 76.06M | 465.34M | 381.82M | 485.99M | 319.14M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 111.50M | 142.06M | 661.78M | 513.21M | 615.11M | 451.45M |
| Total current liabilities | 29.88M | 41.94M | 90.02M | 55.42M | 154.23M | 115.93M |
| Short-term debt | -- | -- | 3.02M | 3.31M | 3.80M | 5.76M |
| Long-term debt | -- | -- | -- | -- | -- | 238.90M |
| Total liabilities | 34,718,000.00 | 47,370,000.00 | 123,012,000.00 | 85,237,000.00 | 191,671,000.00 | 399,375,000.00 |
| Total equity | 76.78M | 94.69M | 538.77M | 427.98M | 423.44M | 52.07M |
| Retained earnings | -- | 0 | -91.12M | -499.29M | -1.35B | -2.08B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 474.83M | 323.62M | 368.33M | 385.65M | 296.56M | 191.51M |
| Cash & ST investments | 404.98M | 260.22M | 319.14M | 347.82M | 267.87M | 161.13M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 550.42M | 409.12M | 451.45M | 466.41M | 370.74M | 263.68M |
| Total current liabilities | 124.32M | 113.02M | 115.93M | 52.08M | 62.66M | 62.77M |
| Short-term debt | 4.70M | 5.51M | 5.76M | 5.90M | 4.67M | 4.74M |
| Long-term debt | 257.07M | 268.27M | 238.90M | 241.91M | 259.48M | 264.29M |
| Total liabilities | 415,828,000.00 | 426,283,000.00 | 399,375,000.00 | 336,906,000.00 | 358,517,000.00 | 361,923,000.00 |
| Total equity | 134.59M | -17.16M | 52.07M | 129.50M | 12.22M | -98.25M |
| Retained earnings | -1.77B | -1.94B | -2.08B | -2.22B | -2.35B | -2.48B |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -75.96M | -145.84M | -297.69M | -331.73M | -582.45M | -609.44M |
| Depreciation & amortization | 72.00K | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| Free cash flow | -78.65M | -146.78M | -338.76M | -334.77M | -586.50M | -610.15M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 283.80M | 243.23M | 666.17M | 189.18M |
| Ending cash balance | 83.51M | 77.06M | 242.60M | 252.12M | 102.54M | 232.78M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | -167.94M | -145.72M | -130.66M | -149.92M | -85.10M | -106.85M |
| Depreciation & amortization | 1.98M | 3.13M | 2.57M | 2.37M | 2.26M | 2.22M |
| Free cash flow | -168.17M | -145.73M | -130.67M | -149.92M | -85.55M | -107.03M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 189.18M | 178.88M | 0 | 0 |
| Ending cash balance | 169.00M | 188.38M | 232.78M | 277.11M | 240.63M | 98.66M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -707.16 | -830.73 | -198.89 | -84.44 | -198.83 | -310.75 |
| ROA %i | -106.43 | -168.64 | -141.89 | -69.48 | -150.03 | -138.54 |
| ROIC %i | -707.16 | -830.73 | -179.72 | -79.14 | -184.23 | -185.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -404.01 | -324.73 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.00 | 2.26 | 6.52 | 7.98 | 3.49 | 3.18 |
| Quick ratioi | 2.76 | 2.05 | 5.68 | 7.13 | 3.15 | 2.75 |
| Debt / assetsi | -- | 1.97 | 5.08 | 6.02 | 5.95 | 63.04 |
| LT debt / equityi | -- | 8.06 | 5.68 | 6.44 | 7.74 | 535.52 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -295.94 | -522.08 | -310.75 | -333.00 | -799.46 | -- |
| ROA %i | -135.38 | -169.65 | -138.54 | -139.99 | -127.41 | -161.32 |
| ROIC %i | -182.69 | -243.02 | -185.47 | -182.27 | -159.60 | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.82 | 2.86 | 3.18 | 7.41 | 4.73 | 3.05 |
| Quick ratioi | 3.26 | 2.30 | 2.75 | 6.68 | 4.28 | 2.57 |
| Debt / assetsi | 52.97 | 76.79 | 63.04 | 61.36 | 80.12 | 113.94 |
| LT debt / equityi | 213.15 | -- | 535.52 | 216.43 | 2,392.14 | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-11-20 20:01:17 · For reference only, not investment advice and not tailored to your situation.
Biohaven discussion 0 comments